Scholarlink

<p>The synergy between electroosmotic flow (EOF) and surface plasmon resonance (SPR) offers a transformative approach to overcome diffusion-limited biosensing. However,&#xa0; existing voltage-driven EOF systems face critical trade-offs between high-voltage requirements and biocompatibility. Here, we present a self-powered electroosmosis-enhanced SPR immunosensor that integrates a triboelectric nanogenerator (TENG) with SPR imaging (SPRi) to achieve ultra-sensitive detection of HER2-positive cancer cells. By leveraging TENG-driven asymmetric alternating electric fields, the developed&#xa0;platform generates electroosmotic vortices that accelerate cellular transport velocity and enhance antigen–antibody binding efficiency, achieving a detection limit of 3 × 10<sup>4</sup> cells/mL—an order of magnitude improvement over label-free SPR methods. Remarkably, the system captures HER2-positive cells within 45&#xa0;s at a high throughput of cell, the detection speed increased by 20-fold. This performance, combined with label-free operation and biocompatibility, establishes a scalable framework for liquid biopsy applications.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rapid HER2-positive cell detection via high-voltage electroosmotic flow-driven microfluidic SPRi

  • 期刊论文

  • 发表日期：

    2025年7月19日

查看全文
  • Xinmeng Zhang,
  • Yue Jiao,
  • Taikang Yang,
  • Zhourui Xu,
  • Yonghong Shao,
  • Jianxun Hou,
  • Gaixia Xu

摘要

The synergy between electroosmotic flow (EOF) and surface plasmon resonance (SPR) offers a transformative approach to overcome diffusion-limited biosensing. However,  existing voltage-driven EOF systems face critical trade-offs between high-voltage requirements and biocompatibility. Here, we present a self-powered electroosmosis-enhanced SPR immunosensor that integrates a triboelectric nanogenerator (TENG) with SPR imaging (SPRi) to achieve ultra-sensitive detection of HER2-positive cancer cells. By leveraging TENG-driven asymmetric alternating electric fields, the developed platform generates electroosmotic vortices that accelerate cellular transport velocity and enhance antigen–antibody binding efficiency, achieving a detection limit of 3 × 104 cells/mL—an order of magnitude improvement over label-free SPR methods. Remarkably, the system captures HER2-positive cells within 45 s at a high throughput of cell, the detection speed increased by 20-fold. This performance, combined with label-free operation and biocompatibility, establishes a scalable framework for liquid biopsy applications.

Graphical Abstract